Cite
HARVARD Citation
Stintzing, S. et al. (2020). Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line treatment of RAS wild-type metastatic colorectal cancer in Germany: data from the FIRE-3 (AIO KRK-0306) study. Journal of medical economics. pp. 448-455. [Online].